Comparative Evaluation Of Antimicrobial Efficacy Among Various Generations Of PRF From A Systemically Healthy Population - An In Vitro Study
Chanchal Katariya*
Saveetha Dental College & Hospital, Chennai, Tamil Nadu, India.
*Corresponding Author
Chanchal Katariya,
Saveetha Dental College & Hospital, Chennai, Tamil Nadu, India.
E-mail: chanchalkatariya0@gmail.com
Received: May 14, 2021; Accepted: August 5, 2021; Published: August 16, 2021
Citation:Chanchal Katariya. Comparative Evaluation Of Antimicrobial Efficacy Among Various Generations Of PRF From A Systemically Healthy Population - An In Vitro Study. Int J Dentistry Oral Sci. 2021;8(8):3801-3804. doi: dx.doi.org/10.19070/2377-8075-21000779
Copyright: Chanchal Katariya©2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Aim: The aim of the study is to study the antibacterial efficacy of different generations of PRF.
Materials And Method: A volume of 5 mL of intravenous blood was obtained from the median cubital vein, PRF- centrifuged
at 3300 rpm for 13 minutes , I-PRF - 700 rpm for 3 minutes, CGF- centrifuged using a one-step protocol: 30sec
acceleration, 2min 2700 rpm, 4min 2400 rpm, 4min 2700 rpm, 3min 3000 rpm, 36sec deceleration and stop, A-PRF+ 1300
rpm for 8 minutes using a centrifuge. The PRF clot was removed from the tube with sterile tweezers and separated from the
RBC base with scissors after centrifugation.
Results: The zone of inhibition was maximum for CGF followed by i-PRF, A-PRF and PRF. The zone of inhibition for PRF-
7MM, I-PRF- 14MM, CGF-15MM and A-PRF- 9MM was seen.
Conclusions: Within the limitations of the study, all the PRF generation PRF, I-PRF, CGF, A-PRF showed antimicrobial efficacy
against oral pathogens. CGF showed maximum inhibiton against the bacteria followed by I-PRF, A-PRF and PRF. This
can be used to advantage for treating periodontal therapy and this might act as aid in tissue regeneration as well.
2.Introduction
6.Conclusion
8.References
Introduction
Periodontitis is defined as an infectious disease resulting in inflammation
within the supporting tissues of the teeth, progressive
attachment and bone loss and is characterized by pocket formation
and/or recession of the gingiva. It is recognized as the
most frequently occurring form of periodontitis. It is prevalent in
adults, but can occur at any age. The disease is usually associated
with the presence of plaque and calculus. Progression of attachment
loss usually occurs slowly, but periods of rapid progression
can occur. Associated with a variable microbial pattern. The goal
of soft and hard tissue regeneration is to replace disfigured periodontal
tissues that have been lost due to periodontal diseases, as
well as to reclaim previously lost alveolar bone and gingiva.One
of the materials used for regenerative purpose is platelet concentrates.
It is used as membrane and as regenerative material as such.
Platelets are 2–3 m in diameter anucleate cytoplasmic fragments
originating from bone marrow megakaryocytes. Many granules,
few mitochondria, and two prominent membrane structures,
the surface-connected canalicular system and the thick tubular
system, are found in these cells. Granules are spherical or oval
structures with diameters ranging from 200 to 500 nm that are
each surrounded by a unit membrane.[1] Platelet-derived growth
factor (PDGF), transforming growth factor (TGF-), and insulinlike
growth factor (IGF-) form an intracellular storage pool of
proteins essential for wound healing (IGF-I). After activation, the
granules fuse with the platelet cell membrane. At least some secretory
proteins are converted into biologically active forms. The
active proteins are then secreted, allowing them to bind to the
target cells' transmembrane receptors. Intracellular signal proteins
are activated after they have been bound. This causes a gene
sequence to be expressed, which regulates cellular proliferation,
collagen synthesis, and osteoid formation, among other things.[2]
Chemotactic and mitogenic properties of these GFs facilitate and
modulate cellular functions involved in tissue healing, regeneration,
and cell proliferation.[3] Platelet concentrates release growth
factors (GFs) and other molecules that modulate the woundhealing
response in both hard and soft tissues when triggered,
which is why they're used. Furthermore, Platelet concentrates’s'
anti-inflammatory effects have resulted in a substantial reduction
in postoperative pain and swelling.[4]
Platelet concentrates have been classified as first and second generation-
first generation is platelet rich plasma (PRP) and second generation is plasma rich fibrin (PRF)[5]. Plasma rich fibrin has
many paradigms under it like Injectable PRF, Leukocyte PRF, Advanced
PRF and so on. The aim of the study is to study the antibacterial
efficacy of each type of PRF.
Materials and Methods
This study was conducted in Saveetha dental college and hospital.
Blood samples were collected from systemically healthy patients
from out patient department of periodontics after getting consent
from the patients. Total of 5 subjects in each group.
Inclusion criteria
1. Systemically healthy patients.
2. Aged between 20-45 years
3. Non-smokers
4. Not on any medication for the past 3months.
Exclusion Criteria
1. Patients with medical history of any systemic illness or surgery.
2. Patients on any medication.
3. Smokers
Preparation of PRF
Plasma Rich Fibrin
A volume of 5 mL of intravenous blood was obtained from the
median cubital vein, which lies within the cubital fossa anterior to
the elbow in the plain bulb and centrifuged at 3300 rpm for 13
minutes using a centrifuge. The PRF clot was removed from the
tube with sterile tweezers and separated from the RBC base with
scissors after centrifugation. By squeezing out the fluids in the
fibrin clot, PRF was obtained in the form of a membrane.
Injectable Plasma Rich Fibrin
A volume of 5 mL of intravenous blood was obtained in the plain
bulb and centrifuged at 700 rpm for 3 minutes using a centrifuge.
The PRF is in liquid form.
Concentrated Growth Factor
A volume of 5 mL of intravenous blood was obtained in the plain
bulb and centrifuged using a one-step protocol: 30sec acceleration,
2min 2700 rpm, 4min 2400 rpm, 4min 2700 rpm, 3min 3000
rpm, 36sec deceleration and stop. The CGF clot was removed
from the tube with sterile tweezers and separated from the RBC
base with scissors after centrifugation. By squeezing out the fluids
in the fibrin clot, CGF was obtained in the form of a membrane.
Advanced Plasma Rich Fibrin:
A volume of 5 mL of intravenous blood was obtained in the
plain bulb and centrifuged at 1300 rpm for 8 minutes using a
centrifuge. The PRF clot was removed from the tube with sterile
tweezers and separated from the RBC base with scissors after
centrifugation. By squeezing out the fluids in the fibrin clot, PRF
was obtained in the form of a membrane.
Microbial assay:
Nutrient agar plate were cultured with streptococcus mutans
strain. A total of four wells were created and labelled as PRF, i-
PRF, A-PRF and CGF. All the type was PRF was placed in their
respective wells and was incubated for 24 hours. Antimicrobial
efficacy was evaluated by the zone of inhibition.
Results
The zone of inhibition was maximum for CGF followed by i-
PRF, A-PRF and PRF. The zone of inhibition for PRF-7MM,
I-PRF- 14MM, CGF-15MM and A-PRF- 9MM was seen.
Discussion
Over the last 20 years, the regenerative capacity of computers has
been thoroughly researched. However, there are only a few studies
about their antimicrobial effects in the literature. In the present
study the zone of inhibition was maximum for CGF followed by
i-PRF, A-PRF and PRF. The zone of inhibition for PRF-7MM,
I-PRF- 14MM, CGF-15MM and A-PRF- 9MM was seen.
Natural components of platelet-rich fibrin (PRF) include (A)
cell types: platelets, leukocytes, and red blood cells; (B) a provisional
extracellular matrix 3-D scaffold made of autologous fibrin,
including fibronectin and vitronectin; (C) a large number
of bioactive molecules, including platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), insulin-like
growth factor (IGF), epidermal growth factor (EGF), transforming
growth factor-beta (TGF-ß), and bone morphogenetic protein-
2; (BMP2) [6, 7] A study concluded that P. gingivalis and A.
actinomycetemcomitans were inhibited by PRP but not by PRF.
[8] Study done in 2018, included that in the case of Pg, I-PRF
had the largest inhibition region, which was substantially larger
than PRF. In addition, PRP had a slightly larger inhibition zone
against PRF. In the case of Aa, PRP had a slightly larger zone
of inhibition than PRF and I-PRF.[9] In 2015, a study compared
the antimicrobial activity of four plasma fractions, that is, PRP,
platelet-poor plasma, platelet-depleted plasma, and PRF against
Pg, Aa, and Fusobacterium nucleatum and found that PRP had
the highest antibacterial activity.[10] In 2016, Joshi et al. published
a study in which PRF showed a strong zone of inhibition against
a subgingival plaque sample, and calorimetric analysis verified that
PRF caused the least amount of turbidity.[10] A study by Kardeet
al. in 2017 where the antibacterial activity of PRP, PRF, and I-PRF
was tested on the supragingival plaque and it was observed that
I-PRF showed a maximum zone of inhibition followed by PRP
and then PRF.[11]
Since platelets are present along with white blood cells and plasma, the exact component of the platelet concentrates responsible
for the antimicrobial activity has yet to be determined. The
antibacterial effect of platelet concentrates has been attributed
to a variety of mechanisms, including the development of oxygen
metabolites such as superoxide, hydrogen peroxide, and hydroxyl-
free radicals, the binding, aggregation, and internalization
of microorganisms, and the release of antimicrobial peptides.
[10] As suggested by Yeaman, direct bacterial killing could result
from platelets' direct association with microorganisms, involvement
in antibody-dependent cell cytotoxicity, and engulfment by
entrapped white blood cells inside PRF. The leukocytes that are
present in much greater concentrations along with the platelets in
these platelet concentrates as compared to the whole blood are
already known for their antibacterial activity.
Many anti-bacterials are used along phase I periodontal therapy to
outgrow the periodontopathic pathogens, but due to bacterial resistance,
alternative methods have been studied to bring about the
antimicrobial activity against these bacteria. One of the methods
is using PRF for its antimicrobial activity along with the release of
growth factor for regenerative purposes. Future scope of the present
study is to work on methods to enhance the anti-microbial
property of various generations of PRF.
Conclusion
Within the limitations of the study, all the PRF generation PRF,
I-PRF, CGF, A-PRF showed antimicrobial efficacy against oral
pathogens. CGF showed maximum inhibiton against the bacteria
followed by I-PRF, A-PRF and PRF. This can be used to advantage
for treating periodontal therapy and this might act as aid in
tissue regeneration as well.
References
- Arakeri G, Brennan PA. Oral submucous fibrosis: an overview of the aetiology, pathogenesis, classification, and principles of management. Br J Oral Maxillofac Surg. 2013 Oct 1;51(7):587-93.
- International Agency for Research on Cancer. Betel-quid and areca nut chewing and some areca nut derived nitrosoamines, vol. 85. Lyon:IARC; 2004. p. 123-129.
- Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, et al. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis. 2011 Apr;17 Suppl 1:42-57. Pubmed PMID: 21382138.
- Chole RH, Gondivkar SM, Gadbail AR, Balsaraf S, Chaudhary S, Dhore SV, et al. Review of drug treatment of oral submucous fibrosis. Oral Oncol. 2012 May 1;48(5):393-8.
- Fedorowicz Z, Shih-Yen EC, Dorri M, Nasser M, Newton T, Shi L. Interventions for the management of oral submucous fibrosis. Cochrane Database Syst. Rev. 2008(4);CD007156.
- Haque MF, Meghji S, Nazir R, Harris M. Interferon gamma (IFN-?) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001 Jan;30(1):12-21.
- Khanna JN, Andrade NN. Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. Int J Oral Maxillofac Surg. 1995 Dec;24(6):433-9.Pubmed PMID: 8636640.
- Patil PG, Parkhedkar RD. New graft-stabilizing clip as a treatment adjunct for oral submucous fibrosis. J Prosthet Dent. 2009 Sep;102(3):191-2.Pubmed PMID: 19703627.
- Cox S, Zoellner H. Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J. Oral Pathol. Med. 2009 Feb;38(2):220-6.
- Gupta DS, Gupta MK, Golhar BL. Oral submucous fibrosis–clinical study and management by physiofibrolysis (MWD). J Indian Dent Assoc. 1980;52(1):375-8.
- Warnakulasuriya S, Kerr AR. Oral submucous fibrosis: a review of the current management and possible directions for novel therapies. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Aug;122(2):232-41.Pubmed PMID: 27422422.
- Chen Z, Chen HB, Huang WX, Huang Q. The clinical effect of microwave radiation in treating oral mucous membrane diseases. J Clin Stomatol. 2006;22:750.
- Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis--a collagen metabolic disorder. J Oral Pathol Med. 2005 Jul;34(6):321-8.Pubmed PMID: 15946178.
- Bhatnagar P, Rai S, Bhatnagar G, Kaur M, Goel S, Prabhat M. Prevalence study of oral mucosal lesions, mucosal variants, and treatment required for patients reporting to a dental school in North India: In accordance with WHO guidelines. J Family Community Med. 2013 Jan;20(1):41-8.Pubmed PMID: 23723730.
- More C, Shah P, Rao N, Pawar R. Oral submucous fibrosis: an overview with evidence-based management. Int J Oral Health Sci Adv. 2015;3(3):40-9.
- Markiewicz MR, Margarone III JE, Barbagli G, Scannapieco FA. Oral mucosa harvest: an overview of anatomic and biologic considerations. EurAssocUrol. 2007 Oct 1;5(5):179-87.
- van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009 Apr-May;45(4-5):317-23.Pubmed PMID: 18674954.
- More CB, Gupta S, Joshi J, Varma SN. Classification system for oral submucous fibrosis. J Indian Acad Oral Med Radiol. 2012;24(1):24-9.
- Maher R, Sankaranarayanan R, Johnson NW, Warnakulasuriya KA. Evaluation of inter-incisor distance as an objective criterion of the severity of oral submucous fibrosis in Karachi, Pakistan. Eur J Cancer B Oral Oncol. 1996 Sep;32B(5):362-4.Pubmed PMID: 8944843.
- Jontell M, Holmstrup H. Red and white lesions of the oral mucosa. In: Greenberg M, Glick M, Ship J, editors. Burket's Oral Medicine. 11th ed. Jericho, England: Hamilton; 2008. p. 88-9. Back to cited text no. 7
- Daftary D, Murti P, Bhonsle R, Gupta P, Mehta F, Pindborg J. Oral precancerous lesions and conditions of tropical interest. In: Prabhu S, Wilson D, Daftary D, Johnson N, editors. Oral Diseases in the Tropics. Jericho, England: Oxford University Press; 1993. p. 417-22.